概括
不建议在腹中使用糖作为口服补水疗法. 口服葡萄糖电解质溶液在治疗腹疾病方面更有效,更安全.
科学领域:
- 临床医学 临床医学
- 胃肠病学 胃肠病学
- 儿科 儿科 儿科
背景情况:
- 口服补水疗法 (ORT) 对于治疗腹疾病至关重要.
- 基于葡萄糖的口服补水溶液 (ORS) 是非常有效的.
- 探索替代碳水化合物,如糖糖对于ORT是很重要的.
研究的目的:
- 评估糖作为口服腹治疗中葡萄糖的潜在替代品.
- 为了比较糖-电解质溶液与葡萄糖-电解质溶液的疗效和安全性.
主要方法:
- 18名腹患者接受了口服的糖糖和电解质维持溶液.
- 监测了液体平衡,血比重和便减少糖的度.
- 治疗结果与口服葡萄糖电解质溶液的已知数据进行了比较.
主要成果:
- 在18名患者中,有15名患者成功地维持了糖糖电解质溶液的治疗.
- 三名患者体验到流体流失的大幅增加和血比重升高,需要停止口服治疗.
- 十二名被测试的患者表现出明显的度的便减少糖,表明吸收不良.
结论:
- 糖对腹的口服补水疗法效果不如葡萄糖,而且可能比葡萄糖更不安全.
- 便中显著减少糖的存在表明糖的吸收受损.
- 葡萄糖仍然是腹疾病中口服补水溶液的首选碳水化合物,这是由于其卓越的疗效和安全性.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Cholera
Cholera is an acute gastrointestinal disease caused by the Gram-negative bacterium Vibrio cholerae. It is transmitted primarily via the fecal-oral route through the ingestion of contaminated water or food.Vibrio cholerae is a motile, Gram-negative bacterium of the family Vibrionaceae, primarily associated with waterborne outbreaks in areas with inadequate sanitation. Although over 200 serogroups of V. cholerae exist, only O1 and O139 are responsible for epidemic cholera. The O1 serogroup,...


